• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Braeburn, Knight seek Health Canada nod for opioid dependence implant

June 13, 2017 By Sarah Faulkner

Braeburn PharmaceuticalsBraeburn Pharmaceuticals and Knight Therapeutics (TSE:GUD) said today that Health Canada has agreed to review Knight’s new drug submission for Probuphine, a buprenorphine subdermal implant designed to treat opioid drug dependence.

In February last year, Braeburn and Knight inked an exclusive distribution and sublicense deal, giving Knight the exclusive right to distribute Probuphine in Canada.

Braeburn’s Probuphine is a 6-month buprenorphine implant for the treatment of opioid addiction and is the 1st device of its kind to be approved by the FDA.

“Probuphine is a unique and innovative product that has the potential to address an important unmet need for opioid dependent patients,” Knight’s CEO Jonathan Ross Goodman said in prepared remarks. “With Probuphine, Knight is continuing to advance its portfolio of opioid supportive therapeutics, which includes Movantik, a product for opioid-induced constipation we in-licensed from AstraZeneca and began commercializing in March of this year.”

“Opioid addiction is an overwhelming public health epidemic in North America. This is another important milestone for Probuphine, an innovative treatment approach with the potential to reduce the risks of diversion, abuse and accidental pediatric exposure,” Braeburn president & CEO Mike Derkacz added. “We look forward to working with Knight and Health Canada to bring this important treatment option to Canadian patients.”

Filed Under: Drug-Device Combinations, Featured, Implants, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, Knight Therapeutics

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS